Guardant gets FDA nod for next-gen cancer mutation blood test
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has given approval to Guardant for a next-generation blood test that detects cancer mutations. This test is a blood-based test, indicating a less invasive method for detecting cancer mutations. The approval is for a next-generation version of such a test.